1. Better therapeutic trials in ovarian cancer.
- Author
-
Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, and Swenerton KD
- Subjects
- Adenocarcinoma, Clear Cell drug therapy, Adenocarcinoma, Mucinous drug therapy, BRCA1 Protein metabolism, BRCA2 Protein metabolism, Carcinoma, Endometrioid drug therapy, Cystadenocarcinoma, Serous drug therapy, Drug Industry, Female, Gene Expression Regulation, Humans, Mutation, National Cancer Institute (U.S.), Neoplasm Grading, Neoplasm Staging, Ovarian Neoplasms genetics, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Patient Selection, Randomized Controlled Trials as Topic standards, Randomized Controlled Trials as Topic trends, Research Support as Topic, United States, Biomarkers, Tumor blood, Drug Screening Assays, Antitumor methods, Drug Screening Assays, Antitumor standards, Drug Screening Assays, Antitumor trends, Molecular Targeted Therapy, Ovarian Neoplasms drug therapy, Randomized Controlled Trials as Topic methods, Research Design
- Abstract
The Ovarian Task Force of the Gynecologic Cancer Steering Committee convened a clinical trials planning meeting on October 28-29, 2011, with the goals to identify key tumor types, associated molecular pathways, and biomarkers for targeted drug intervention; review strategies to improve early-phase screening, therapeutic evaluation, and comparison of new agents; and optimize design of randomized trials in response to an evolving landscape of scientific, regulatory, and funding priorities. The meeting was attended by international clinical and translational investigators, pharmaceutical industry representatives, government regulators, and patient advocates. Panel discussions focused on disease types, early-phase trials, and randomized trials. A manuscript team summarized the discussions and assisted with formulating key recommendations. A more integrated and efficient approach for screening new agents using smaller selective randomized trials in specific disease-type settings was endorsed, together with collaborative funding models between industry and the evolving national clinical trials network, as well as efforts to enhance public awareness and study enrollment through advocacy.
- Published
- 2014
- Full Text
- View/download PDF